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Introduction {#jdi12135-sec-0005}
============

Type 2 diabetes is a well‐known risk factor for cardiovascular disease. Several experimental results suggest that postprandial hyperglycemic spikes contribute to the pathophysiology of diabetic cardiovascular complications. The suppression of postprandial hyperglycemia is therefore a promising approach for preventing cardiovascular disease in type 2 diabetes[1](#jdi12135-bib-0001){ref-type="ref"}.

α‐Glucosidase inhibitors (αGIs) are widely used for the primary treatment of type 2 diabetes. They inhibit maltase, sucrase and other disaccharide hydrolases (i.e., suppress the degradation of disaccharides to monosaccharides) in the brush border membrane of the small intestine[2](#jdi12135-bib-0002){ref-type="ref"}. Therefore, αGIs can improve postprandial hyperglycemia by delaying carbohydrate absorption. The Study to Prevent Non‐Insulin‐Dependent Diabetes Mellitus trial[3](#jdi12135-bib-0003){ref-type="ref"} showed that treatment with an αGI, acarbose, is associated with a significant risk reduction in cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Subsequently, much attention has been focused on αGIs as therapeutic agents for type 2 diabetes and its complications.

Weight gain in type 2 diabetes not only worsens diabetic control, but also increases the risk of diabetes‐associated cardiovascular complications[4](#jdi12135-bib-0004){ref-type="ref"}. However, glycemic control with insulin or certain oral hypoglycemic agents (insulin secretagogues and thiazolidinediones) promotes weight gain[5](#jdi12135-bib-0005){ref-type="ref"}. In contrast, biguanides and incretin‐related drugs (glucagon‐like peptide 1 \[GLP‐1\] analogs and dipeptidyl peptidase 4 inhibitors) have beneficial effects on bodyweight. Meanwhile, the effects of αGIs on bodyweight control remain unclear. Whereas some studies suggest that αGIs can reduce bodyweight in type 2 diabetes[3](#jdi12135-bib-0003 jdi12135-bib-0006){ref-type="ref"}, a meta‐analysis of randomized controlled trials with acarbose showed that it has minor effects for lowering bodyweight[7](#jdi12135-bib-0007){ref-type="ref"}.

Three αGIs are now clinically available in Japan: acarbose, miglitol and voglibose. However, to our knowledge, there have been no reports comparing these drugs head‐to‐head. In the present study, we evaluated the effects of these three αGIs on glycemic control, weight management and other clinical measures in the treatment of Japanese patients with obese type 2 diabetes.

Materials and Methods {#jdi12135-sec-0006}
=====================

The present study was a multicenter (Nippon Medical School Hospital; Saitama Medical Center, Jichi Medical University; Hachijo Municipal Hospital; Kashiwa City Hospital; and Otonari Medical Clinic), open‐label, randomized study. The protocol was approved by each institutional ethics review board, and all participants were enrolled after being informed of the clinical trial and providing written consent.

Participants {#jdi12135-sec-0007}
------------

The study included 81 outpatients (38 men and 43 women) with obese type 2 diabetes (aged ≥40 years; glycated hemoglobin \[HbA1c\] 6.4--8.4%; body mass index \[BMI\] ≥25 kg/m^2^). HbA1c was measured by the latex agglutination method and expressed as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%)[8](#jdi12135-bib-0008 jdi12135-bib-0009){ref-type="ref"}. Patients who had received insulin therapy or αGI medication, or had a serious hepatic, renal, or cardiac disease were excluded.

Study Design {#jdi12135-sec-0008}
------------

After the informed consent was obtained, an application form was sent to an external registration center by facsimile. Approved participants were allocated to one of four treatment groups using a random number list for miglitol (150 mg/day), acarbose (300 mg/day), voglibose (0.9 mg/day) and control (no additive medication). The dose of miglitol was not the maximum dose approved in Japan (225 mg/day), whereas acarbose and voglibose were used at maximum doses, because these doses are generally used in practice. All patients underwent a 12‐week therapy with the assigned regimen, and were instructed to maintain their usual diet and medications over the study period.

Anthropometric measurements and blood sample tests were carried out after an overnight fast at baseline, and 4, 8 and 12 weeks after the treatment. The primary end‐points were HbA1c, bodyweight and BMI, as well as their changes from baseline after drug treatment. The secondary end‐points included other glycemic parameters (fasting plasma glucose \[FPG\] and serum insulin), serum lipids (total cholesterol \[TC\], low‐density lipoprotein cholesterol \[LDL‐C\], high‐density lipoprotein cholesterol \[HDL‐C\] and triacylglycerols \[TG\]) and adipocytokines (leptin and adiponectin). All patients completed questionnaires about their digestive symptoms (borborygmus, abdominal distension, flatulence and fecal condition), appetite and drug compliance every 4 weeks.

Statistical Analyses {#jdi12135-sec-0009}
--------------------

The clinical characteristics of patients were analyzed by the χ^2^‐test or one‐way analysis of variance ([anova]{.smallcaps}). The changes over the study period were analyzed by two‐way [anova]{.smallcaps} with Bonferroni correction. Intergroup differences were analyzed by two‐way repeated‐measures [anova]{.smallcaps} with Bonferroni correction. The questionnaire results were analyzed by the Friedman test with Bonferroni correction. The level of statistical significance was set at *P *\< 0.05. Associations between changes in HbA1c and bodyweight were evaluated by Pearson\'s correlation coefficient analysis. All statistical analyses were carried out using SPSS for Windows, Japanese version 16.0 (SPSS Institute Inc., Tokyo, Japan).

Results {#jdi12135-sec-0010}
=======

Of the 81 enrolled patients, 78 had sufficient baseline and follow‐up data to evaluate the primary end‐points (Figure [1](#jdi12135-fig-0001){ref-type="fig"}). Two patients in the control group and one in the acarbose group with insufficient data were excluded from the statistical analysis. The baseline characteristics of the study participants are shown in Table [1](#jdi12135-tbl-0001){ref-type="table-wrap"}. There were no significant differences in the clinical characteristics among the four groups.

###### Baseline characteristics of the participants

                                     Control       Miglitol      Acarbose      Voglibose     Significance
  ---------------------------------- ------------- ------------- ------------- ------------- --------------
  No. of patients                    22            18            22            19            
  Male/female                        7/15          10/8          13/9          8/11          NS
  Age (years)                        66.6 ± 13.0   66.3 ± 9.3    61.8 ± 13.7   66.7 ± 12.3   NS
  Height (cm)                        155 ± 9.5     156 ± 9.8     159 ± 10.3    157 ± 8.4     NS
  Bodyweight (kg)                    69.6 ± 14.3   67.8 ± 11.2   72.7 ± 11.5   70.8 ± 11.3   NS
  BMI (kg/m^2^)                      28.7 ± 3.1    28.2 ± 3.1    28.6 ± 2.7    28.9 ± 5.3    NS
  HbA1c, NGSP (%)                    7.26 ± 0.79   7.08 ± 0.61   7.11 ± 0.66   7.14 ± 0.59   NS
  FPG (mmol/L)                       7.55 ± 1.34   7.10 ± 1.05   7.71 ± 1.63   7.00 ± 1.32   NS
  Total cholesterol (mmol/L)         5.00 ± 0.74   5.07 ± 0.79   5.21 ± 1.26   4.75 ± 0.72   NS
  LDL cholesterol (mmol/L)           3.06 ± 0.86   3.08 ± 0.78   3.28 ± 0.84   2.67 ± 0.50   NS
  HDL cholesterol (mmol/L)           1.39 ± 0.29   1.37 ± 0.25   1.39 ± 0.36   1.23 ± 0.30   NS
  TG (mmol/L)                        1.57 ± 0.75   1.42 ± 0.44   1.57 ± 0.99   1.41 ± 0.63   NS
  Concomitant medications, *n* (%)                                                           
  Oral hypoglycemic agents           19 (86.4)     12 (66.7)     15 (68.2)     16 (84.2)     NS
  Sulfonylurea                       6 (27.3)      8 (44.4)      8 (36.4)      8 (42.1)      NS
  Glinide                            8 (36.4)      2 (11.1)      4 (18.2)      3 (15.8)      NS
  DPP‐4 inhibitor                    0 (0.0)       0 (0.0)       0 (0.0)       1 (5.3)       NS
  Thiazolidinedione                  3 (13.6)      3 (16.7)      1 (4.6)       3 (15.8)      NS
  Metformin                          11 (50.0)     5 (27.8)      11 (50.0)     8 (42.1)      NS
  Hypotensive agents                 18 (81.8)     14 (77.8)     11 (50.0)     15 (79.0)     NS
  Hypolipidemic agents               11 (50.0)     4 (22.2)      8 (36.4)      10 (52.6)     NS

Data are expressed as mean ± standard deviation. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; TG, triacylglycerols; DPP‐4, dipeptidyl peptidase 4. NS, not significant (*P *≥ 0.05).
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![Flow diagram of the study.](jdi-5-206-g1){#jdi12135-fig-0001}

Primary Endpoints {#jdi12135-sec-0011}
-----------------

Table [2](#jdi12135-tbl-0002){ref-type="table-wrap"} shows HbA1c, bodyweight, and BMI in the four groups. In the control group, HbA1c increased significantly from baseline at 12 weeks of treatment. In the miglitol group, HbA1c decreased significantly from baseline at 4 weeks, and the decreased HbA1c level was kept over the study period. In the voglibose group, a significant decrease was observed in HbA1c after 12 weeks of treatment. HbA1c did not change significantly in the acarbose group over the study period (Table [2](#jdi12135-tbl-0002){ref-type="table-wrap"}). In addition, the changes in HbA1c from baseline (ΔHbA1c) in the miglitol group were greater than those in the control group at 8 and 12 weeks of treatment (Figure [2](#jdi12135-fig-0002){ref-type="fig"}a).

###### Changes in glycated hemoglobin, bodyweight and body mass index during the study period (primary end‐points)

                    Baseline      4 weeks                                               8 weeks                                                   12 weeks
  ----------------- ------------- ----------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------------------------------------------
  HbA1c (%)                                                                                                                                       
  Control           7.24 ± 0.81   7.21 ± 0.69                                           7.34 ± 0.78                                               7.47 ± 0.78[\*](#jdi12135-note-0002){ref-type="fn"}
  Miglitol          7.08 ± 0.61   6.89 ± 0.64[\*](#jdi12135-note-0002){ref-type="fn"}   6.77 ± 0.59[\*\*\*](#jdi12135-note-0002){ref-type="fn"}   6.73 ± 0.58[\*\*\*](#jdi12135-note-0002){ref-type="fn"} [†](#jdi12135-note-0002){ref-type="fn"}
  Acarbose          7.12 ± 0.68   7.04 ± 0.61                                           7.04 ± 0.67                                               7.06 ± 0.72
  Voglibose         7.14 ± 0.59   7.03 ± 0.57                                           6.97 ± 0.70                                               6.94 ± 0.80[\*](#jdi12135-note-0002){ref-type="fn"}
  Bodyweight (kg)                                                                                                                                 
  Control           69.9 ± 14.7   69.6 ± 14.8                                           69.8 ± 14.9                                               69.6 ± 15.2
  Miglitol          69.0 ± 11.1   68.5 ± 11.1[\*](#jdi12135-note-0002){ref-type="fn"}   68.2 ± 11.4[\*\*\*](#jdi12135-note-0002){ref-type="fn"}   67.8 ± 11.2[\*\*\*](#jdi12135-note-0002){ref-type="fn"}
  Acarbose          72.1 ± 11.4   72.0 ± 11.7                                           72.2 ± 11.5                                               71.9 ± 12.0
  Voglibose         70.8 ± 11.3   70.5 ± 11.3                                           70.4 ± 11.1                                               70.2 ± 11.0
  BMI (kg/m^2^)                                                                                                                                   
  Control           28.6 ± 3.1    28.5 ± 3.1                                            28.6 ± 3.2                                                28.5 ± 3.3
  Miglitol          28.2 ± 3.1    28.0 ± 3.1[\*](#jdi12135-note-0002){ref-type="fn"}    27.8 ± 3.2[\*\*\*](#jdi12135-note-0002){ref-type="fn"}    27.7 ± 3.1[\*\*\*](#jdi12135-note-0002){ref-type="fn"}
  Acarbose          28.7 ± 2.7    28.6 ± 2.9                                            28.7 ± 2.9                                                28.6 ± 2.9
  Voglibose         28.9 ± 5.3    28.8 ± 5.2                                            28.8 ± 5.1                                                28.6 ± 4.9

Data are expressed as mean ± standard deviation. BMI, body mass index; HbA1c, glycated hemoglobin. \**P *\< 0.05, \*\*\**P *\< 0.001 vs baseline. †*P *\< 0.05 vs control group.
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![Changes in (a) glycated hemoglobin (ΔHbA1c), (b) bodyweight (ΔBW) and (c) body mass index (ΔBMI) from baseline. Data are expressed as mean ± standard error of the mean. \**P *\<* *0.05, \*\*\**P *\< 0.001 vs baseline. †*P *\< 0.05, ††*P *\< 0.01 vs control group. ○, Control; ♦, miglitol; ▲, acarbose; ■, voglibose.](jdi-5-206-g2){#jdi12135-fig-0002}

The bodyweight of the miglitol group decreased significantly from baseline at 4, 8 and 12 weeks of treatment, whereas no significant bodyweight changes were observed in any other groups over the study period (Table [2](#jdi12135-tbl-0002){ref-type="table-wrap"} and Figure [2](#jdi12135-fig-0002){ref-type="fig"}b). Consequently, BMI was decreased from baseline only in the miglitol group at 4, 8 and 12 weeks (Table [2](#jdi12135-tbl-0002){ref-type="table-wrap"} and Figure [2](#jdi12135-fig-0002){ref-type="fig"}c). However, no significant differences were observed in the changes from baseline in bodyweight (ΔBW) or BMI (ΔBMI) among the four groups (Figure [2](#jdi12135-fig-0002){ref-type="fig"}b,c).

There were significant correlations between ΔHbA1c and ΔBW at 12 weeks in the miglitol (*r* = 0.759, *P *\< 0.001) and voglibose (*r* = 0.667, *P *= 0.002) groups (Figure [3](#jdi12135-fig-0003){ref-type="fig"}b,d). A similar correlation was observed between ΔHbA1c and ΔBW at 12 weeks in all participants (*r* = 0.476, *P *\< 0.001; Figure [3](#jdi12135-fig-0003){ref-type="fig"}e). No significant correlations were observed in the control and acarbose groups (Figure [3](#jdi12135-fig-0003){ref-type="fig"}a,c).

![Correlations between changes in glycated hemoglobin (ΔHbA1c) and bodyweight (ΔBW) over 12 weeks. (a) Control, (b) miglitol, (c) acarbose, (d) voglibose group and (e) total participants. ○, Control; ♦, miglitol; ▲, acarbose; ■, voglibose.](jdi-5-206-g3){#jdi12135-fig-0003}

Secondary End‐points {#jdi12135-sec-0012}
--------------------

Over the study period, neither FPG nor serum insulin was changed significantly in any groups. In addition, no significant changes were observed in serum lipid profiles or adipocytokines at any time‐point in any groups (Table [3](#jdi12135-tbl-0003){ref-type="table-wrap"}).

###### Changes in fasting plasma glucose, serum insulin, serum lipids and adipocytokines during the study period (secondary end‐points)

                               Baseline      4 weeks       8 weeks       12 weeks
  ---------------------------- ------------- ------------- ------------- -------------
  FPG (mmol/L)                                                           
  Control                      7.43 ± 1.47   7.47 ± 1.04   7.60 ± 1.29   7.50 ± 1.37
  Miglitol                     7.22 ± 1.05   7.12 ± 0.96   7.16 ± 1.10   7.11 ± 1.46
  Acarbose                     7.41 ± 1.59   7.39 ± 1.13   7.36 ± 1.51   7.10 ± 1.00
  Voglibose                    6.65 ± 1.24   6.94 ± 1.32   6.80 ± 1.40   6.67 ± 1.54
  Serum insulin (pmol/L)                                                 
  Control                      80.2 ± 47.4   87.3 ± 75.6   87.7 ± 66.1   70.2 ± 33.9
  Miglitol                     63.4 ± 49.2   60.8 ± 45.5   54.8 ± 41.7   61.6 ± 49.3
  Acarbose                     80.9 ± 54.3   101 ± 58.1    161 ± 191     68.0 ± 38.1
  Voglibose                    75.3 ± 38.6   96.7 ± 86.2   69.4 ± 36.4   79.3 ± 41.2
  Total cholesterol (mmol/L)                                             
  Control                      4.78 ± 0.61   4.96 ± 0.61   4.94 ± 0.65   5.01 ± 0.55
  Miglitol                     5.12 ± 0.90   5.23 ± 1.03   5.62 ± 1.21   5.43 ± 1.29
  Acarbose                     5.30 ± 1.44   5.53 ± 1.23   5.48 ± 1.39   5.42 ± 1.76
  Voglibose                    4.88 ± 0.66   4.79 ± 0.49   4.58 ± 0.69   4.81 ± 0.57
  LDL cholesterol (mmol/L)                                               
  Control                      3.00 ± 0.96   2.94 ± 0.81   2.86 ± 0.67   3.00 ± 0.75
  Miglitol                     3.04 ± 0.85   3.15 ± 0.82   3.08 ± 0.87   2.87 ± 0.79
  Acarbose                     3.24 ± 0.73   3.23 ± 0.73   3.32 ± 0.91   3.07 ± 1.12
  Voglibose                    2.64 ± 0.56   2.67 ± 0.66   2.82 ± 0.54   2.80 ± 0.59
  HDL cholesterol (mmol/L)                                               
  Control                      1.37 ± 0.28   1.32 ± 0.27   1.35 ± 0.27   1.31 ± 0.28
  Miglitol                     1.39 ± 0.28   1.40 ± 0.26   1.39 ± 0.28   1.38 ± 0.31
  Acarbose                     1.36 ± 0.26   1.39 ± 0.22   1.35 ± 0.30   1.33 ± 0.18
  Voglibose                    1.27 ± 0.29   1.23 ± 0.31   1.23 ± 0.24   1.22 ± 0.25
  TG (mmol/L)                                                            
  Control                      1.52 ± 0.69   1.71 ± 1.27   1.63 ± 0.81   1.68 ± 0.81
  Miglitol                     1.56 ± 0.37   1.48 ± 0.69   1.34 ± 0.50   1.56 ± 1.20
  Acarbose                     1.66 ± 1.14   1.48 ± 1.02   1.95 ± 1.85   1.59 ± 0.94
  Voglibose                    1.39 ± 0.68   1.62 ± 1.45   1.35 ± 0.67   1.37 ± 0.37
  Adiponectin (μg/mL)                                                    
  Control                      9.98 ± 6.06   10.1 ± 7.59   10.1 ± 6.53   9.97 ± 5.87
  Miglitol                     9.96 ± 4.05   9.88 ± 4.84   10.3 ± 5.81   10.3 ± 5.80
  Acarbose                     8.91 ± 3.78   8.26 ± 2.89   8.66 ± 2.94   8.27 ± 2.03
  Voglibose                    13.0 ± 13.6   11.2 ± 11.6   12.9 ± 15.8   12.3 ± 11.5
  Leptin (ng/mL)                                                         
  Control                      11.3 ± 6.42   12.1 ± 8.88   11.6 ± 6.63   11.8 ± 7.80
  Miglitol                     6.98 ± 3.95   6.73 ± 3.56   7.08 ± 4.87   7.41 ± 4.17
  Acarbose                     11.7 ± 8.35   12.0 ± 7.35   12.5 ± 8.49   10.0 ± 7.41
  Voglibose                    11.1 ± 7.68   10.1 ± 7.02   11.1 ± 7.91   10.7 ± 8.42

Data are expressed as mean ± standard deviation. FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; TG, triacylglycerols.
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Questionnaire {#jdi12135-sec-0013}
-------------

The questionnaire data on digestive symptoms showed that the participants in the three αGI‐treated groups experienced some digestive symptoms. Participants in the acarbose group in particular reported increased incidences of persistent borborygmus, abdominal distension and flatulence (Table S1). No distinct differences were observed among the groups with respect to drug compliance or appetite.

Discussion {#jdi12135-sec-0014}
==========

In the present study, we evaluated the effects of three αGIs on glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes. Miglitol and voglibose lowered HbA1c, whereas only miglitol reduced bodyweight and BMI.

αGIs retard carbohydrate digestion and absorption, and thus reduce postprandial hyperglycemia. Among the three αGIs, miglitol differs from acarbose and voglibose with respect to pharmacokinetics. After oral administration, acarbose and voglibose are practically not absorbed[10](#jdi12135-bib-0010 jdi12135-bib-0011){ref-type="ref"}. In contrast, miglitol presents at a high concentration in the upper small intestine and is subsequently absorbed[12](#jdi12135-bib-0012){ref-type="ref"}. Such differences in pharmacokinetics could contribute to the superior therapeutic benefit of miglitol; that is, it can suppress the postprandial blood glucose elevation most effectively. Indeed, recent studies with continuous glucose monitoring showed that miglitol strongly reduces postprandial blood glucose levels in type 2 diabetes[13](#jdi12135-bib-0013 jdi12135-bib-0014){ref-type="ref"}. Although there were no concurrent changes in fasting plasma glucose or insulin levels, adequate suppression of postprandial hyperglycemia could contribute to the rapid and persistent reduction of HbA1c in the miglitol group. Meanwhile, in the present study, HbA1c did not show a significant decrease in the acarbose group. Most of the previous intervention studies with acarbose were carried out for much longer durations, and reported that acarbose treatment significantly reduced HbA1c[7](#jdi12135-bib-0007){ref-type="ref"}. Therefore, the relatively short study period (12 weeks) might obscure the blood glucose‐lowering effect of acarbose.

Intensive diabetic therapies with insulin and its secretagogues increase the risk of weight gain in type 2 diabetes[15](#jdi12135-bib-0015 jdi12135-bib-0016){ref-type="ref"}. Weight gain and obesity could induce insulin resistance and increase the risk of cardiovascular diseases in such patients. In the present study, a weight‐lowering effect was observed only in the miglitol group. The effects of miglitol on incretins might be one of the reasons for this result. Recent studies suggest that miglitol enhances the release of GLP‐1 whilst it suppresses the release of glucose‐dependent insulinotropic polypeptide (GIP) by increasing glucose absorption from the lower small intestine[17](#jdi12135-bib-0017 jdi12135-bib-0018){ref-type="ref"}. Indeed, elevated GLP‐1 contributes to appetite control by inhibiting gastrointestinal motility[19](#jdi12135-bib-0019){ref-type="ref"} and inducing satiety[20](#jdi12135-bib-0020){ref-type="ref"} through the central nervous system. In fact, Arakawa *et al*.[21](#jdi12135-bib-0021){ref-type="ref"} report that miglitol affects postprandial GLP‐1 secretion more strongly than acarbose in patients with visceral obesity, and several reports suggest that miglitol increases GLP‐1 and decreases GIP to greater extents than voglibose after a single[22](#jdi12135-bib-0022){ref-type="ref"} or long‐term[6](#jdi12135-bib-0006){ref-type="ref"} administration in type 2 diabetes. Further analysis for the modulation of postprandial incretin levels with αGIs could explain the differences in the weight‐lowering effects among αGIs.

We did not find any changes in fasting plasma lipid profiles in the present study. However, a meta‐analysis of acarbose showed a small tendency towards decreased fasting TG levels[7](#jdi12135-bib-0007){ref-type="ref"}. In addition, some studies showed that postprandial TG decreased significantly in accordance with decreased insulin levels with acute[23](#jdi12135-bib-0023 jdi12135-bib-0024){ref-type="ref"} or long‐term[24](#jdi12135-bib-0024){ref-type="ref"} acarbose treatment in type 2 diabetes. These data suggest that the improvement of insulin resistance by αGIs might suppress postprandial TG elevation. Hence, postprandial insulin and TG levels should be assessed to further understand the lipid‐lowering effect of each αGI.

After the 12‐week αGI treatment, a significant decrease in HbA1c was observed in the miglitol and voglibose groups, but not in the acarbose group. In addition, a significant correlation was observed between ΔHbA1c and ΔBW in the miglitol and voglibose groups. Thus, the improved glycemic control with these αGIs might be partly due to weight reduction. A few studies suggest that acarbose and miglitol increase plasma adiponectin levels[25](#jdi12135-bib-0025 jdi12135-bib-0026){ref-type="ref"}. Although reductions in bodyweight and body fat mass by αGIs are speculated to modulate adipocytokine levels, adiponectin and leptin levels did not change in any groups of the present study. Other pathways, such as those involving incretins, could contribute to both the better glycemic control and bodyweight reduction by αGIs. Miglitol[17](#jdi12135-bib-0017){ref-type="ref"} and voglibose[27](#jdi12135-bib-0027){ref-type="ref"} have been reported to increase postprandial incretin levels in patients with type 2 diabetes, whereas acarbose has not[28](#jdi12135-bib-0028){ref-type="ref"}, in placebo‐controlled studies. Further research into the underlying mechanisms of the different effects on glycemic control and bodyweight among αGIs is necessary for better understanding of the characteristics of these drugs.

The present study had several limitations. First, this study was an open‐label study with a small sample size, though the participants were randomized and a control group was included. Second, we did not evaluate postprandial levels of plasma glucose, insulin and incretins. These postprandial measures would provide direct information on the effects of αGI. Third, we did not select the maximum dose permitted in Japan in the miglitol group. If the maximum dose was selected, it could be preferable to the present dose for both blood glucose and bodyweight control in the miglitol group. However, as the dose of αGI is increased, the side‐effects such as abdominal symptoms might be likely to occur. It remains to be elucidated whether the maximum dose of miglitol would have superior efficacy with good tolerability. Fourth, we investigated only patients with obese type 2 diabetes. Whether similar effects of miglitol are observed in other types of diabetes or individuals with impaired glucose tolerance is of particular interest. Further investigation is required to better understand these characteristics of each αGI.

In conclusion, the present findings show that miglitol and voglibose lowered HbA1c in patients with obese type 2 diabetes. In addition, miglitol reduced bodyweight within a short period (4 weeks of treatment). These results suggest that miglitol is a preferable agent for improving glycemic control with promoting bodyweight reduction. Further studies on the characteristics of each αGI could provide better treatment options, not only for blood glucose control with bodyweight management, but also for preventing complications in type 2 diabetes.

Supplementary Material
======================

###### 

**Table S1 \|** Questionnaire survey data.

###### 

Click here for additional data file.
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